Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 1/20 | 0.41 |
| ▸ | MAP3K5 | Q99683 | 6/20 | 0.41 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | GRAMD1A | Q96CP6 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.38 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.38 |
| ▸ | NAMPT | P43490 | 1/20 | 0.36 |
| ▸ | SLC34A1 | Q06495 | 1/20 | 0.35 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.35 |
| ▸ | GCK | P35557 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20364361 | 0.87 | ESR2 (0.55) | ESR2MAP3K5NR1H2GRAMD1AROCK2 | |
| SCHEMBL20162123 | 0.85 | WNT1 (0.35) | — | |
| SCHEMBL20364366 | 0.83 | MAPT (0.41) | ESR2MAP3K5NR1H2MAPTGRAMD1A | |
| SCHEMBL721062 | 0.83 | ESR2 (0.48) | ESR2MAP3K5NR1H2MAPTGRAMD1A | |
| SCHEMBL20169979 | 0.82 | ESR2 (0.43) | ESR2MAP3K5NR1H2MAPTGRAMD1A | |
| SCHEMBL20364368 | 0.81 | MAP3K5 (0.40) | ESR2MAP3K5NR1H2MAPTGRAMD1A | |
| SCHEMBL722429 | 0.80 | ESR2 (0.49) | ESR2NR1H2MAPTGRAMD1AMAPK1 | |
| SCHEMBL29042343 | 0.79 | ESR2 (0.51) | ESR2NR1H2MAPTGRAMD1AMAPK1 | |
| SCHEMBL20162154 | 0.78 | MAP3K5 (0.37) | ESR2MAP3K5NR1H2MAPTGRAMD1A | |
| SCHEMBL20162166 | 0.78 | ESR2 (0.49) | ESR2MAP3K5NR1H2MAPTGRAMD1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10294237-B2 | Bicyclic heterocyclic amide derivative | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2019-05-21 | — | — | US | disclosed |
| US-20180194773-A1 | BICYCLIC HETEROCYCLIC AMIDE DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2018-07-12 | — | — | US | disclosed |
| US-20180194773-A1 | BICYCLIC HETEROCYCLIC AMIDE DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2018-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10294237-B2 | Bicyclic heterocyclic amide derivative | NR0B1, NR2E1, NR0B2 | ESR2 620/4885MAP3K5 3026/4885NR1H2 313/4885 |
| US-20180194773-A1 | BICYCLIC HETEROCYCLIC AMIDE DERIVATIVE | NR0B1, NR2E1, NR0B2 | ESR2 620/4885MAP3K5 3026/4885NR1H2 313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.